Donor programmed cell death 1 ligand 1 is required for organ transplant tolerance in major histocompatibility complex-mismatched mixed chimeras although programmed cell death 1 ligand 1 and major histocompatibility complex class II are not required for chimerism

被引:2
|
作者
Huang, Yaxun [1 ,2 ,3 ]
Wu, Xiwei [4 ]
Tang, Shanshan [2 ,3 ]
Wu, Huiqing [5 ]
Nasri, Ubaydah [2 ,3 ]
Qin, Qi [2 ,3 ,6 ]
Song, Qingxiao [2 ,3 ]
Wang, Bixin [2 ,3 ,7 ]
Tao, Hansen [8 ]
Chong, Anita S. [9 ]
Riggs, Arthur D. [2 ]
Zeng, Defu [2 ,3 ,10 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Liver Transplantat, Changsha 410011, Hunan, Peoples R China
[2] City Hope Natl Med Ctr, Beckman Res Inst, Arthur Riggs Diabet & Metab Res Inst, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Beckman Res Inst, Hematol Malignancies & Stem Cell Transplantat Ins, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Beckman Res Inst, Dept Computat & Quantitat Med, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA
[6] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan, Peoples R China
[7] Fujian Med Univ, Union Hosp, Ctr Translat Med Hematol, Fuzhou, Peoples R China
[8] Summer Student Acad City Hope, Arthur Riggs Diabet & Metab Res Inst, Duarte, CA USA
[9] Univ Chicago, Dept Surg, Sect Transplantat, Chicago, IL USA
[10] City Hope Natl Med Ctr, Beckman Res Inst, Arthur Riggs Diabet & Metab Res Inst, Dept Immunol Theranost, 1500 East Duarte Rd, Duarte, CA 91010 USA
关键词
organ transplant tolerance; mixed chimerism; PD-L1; MHC II; REGULATORY T-CELLS; BONE-MARROW; TGF-BETA; PD-1; AUTOIMMUNITY; REJECTION; CD8; EXPRESSION; GENERATION; STABILITY;
D O I
10.1016/j.ajt.2023.04.022
中图分类号
R61 [外科手术学];
学科分类号
摘要
Induction of major histocompatibility complex (MHC) human leukocyte antigen (HLA)-mismatched mixed chimerism is a promising approach for organ transplantation tolerance; however, human leukocyte antigen-mismatched stable mixed chimerism has not been achieved in the clinic. Tolerogenic dendritic cell (DC) expression of MHC class II (MHC II) and programmed cell death 1 ligand 1 (PD-L1) is important for immune tolerance, but whether donor-MHC II or PD-L1 is required for the induction of stable MHC-mismatched mixed chimerism and transplant tolerance is unclear. Here, we show that a clinically applicable radiation-free regimen can establish stable MHC-mismatched mixed chimerism and organ transplant tolerance in murine models. Induction of MHC-mismatched mixed chimerism does not require donor cell expression of MHC II or PD-L1, but donor-type organ transplant tolerance in the mixed chimeras (MC) requires the donor hematopoietic cells and the organ transplants to express PD-L1. The PD-L1 expressed by donor hematopoietic cells and the programmed cell death 1 expressed by host cells augment host-type donor -reactive CD4+ and CD8+ T cell anergy/exhaustion and differentiation into peripheral reg-ulatory T (pTreg) cells in association with the organ transplant tolerance in the MC. Conversely, host-type Treg cells augment the expansion of donor-type tolerogenic CD8+ DCs that express PD-L1. These results indicate that PD-L1 expressed by donor-type tol-erogenic DCs and expansion of host-type pTreg cells in MHC-mismatched MCs play critical roles in mediating organ transplant tolerance.
引用
收藏
页码:1116 / 1129
页数:14
相关论文
共 50 条
  • [1] Harnessing mixed chimerism and programmed cell death protein 1/programmed death ligand 1 signaling for transplant tolerance
    Li, Shuang
    Zou, Dawei
    AMERICAN JOURNAL OF TRANSPLANTATION, 2024, 24 (01) : 147 - 148
  • [2] Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
    Roemer, Margaretha G. M.
    Redd, Robert A.
    Cader, Fathima Zumla
    Pak, Christine J.
    Abdelrahman, Sara
    Ouyang, Jing
    Sasse, Stephanie
    Younes, Anas
    Fanale, Michelle
    Santoro, Armando
    Zinzani, Pier Luigi
    Timmerman, John
    Collins, Graham P.
    Ramchandren, Radhakrishnan
    Cohen, Jonathon B.
    De Boer, Jan Paul
    Kuruvilla, John
    Savage, Kerry J.
    Trneny, Marek
    Ansell, Stephen
    Kato, Kazunobu
    Farsaci, Benedetto
    Sumbul, Anne
    Armand, Philippe
    Neuberg, Donna S.
    Pinkus, Geraldine S.
    Ligon, Azra H.
    Rodig, Scott J.
    Shipp, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (10) : 942 - +
  • [3] Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts
    Yu, Wesley Y.
    Berger, Timothy G.
    North, Jeffrey P.
    Laszik, Zoltan
    Cohen, Jarish N.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (05) : 1127 - 1133
  • [4] Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance
    Wang, Liqing
    Han, Rongxiang
    Hancock, Wayne W.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (10) : 2983 - 2990
  • [5] Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
    Nada, Hanan R.
    Mourad, Ahmed
    Rashed, Laila A.
    El-Hanafy, Ghada M.
    Abdallah, Nermeen M. A.
    Abdelhady, Mohamed M.
    JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY, 2025, 22 (01): : 79 - 87
  • [6] Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
    Pezeshki, Parmida Sadat
    Mahdavi Sharif, Pouya
    Rezaei, Nima
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (12) : 1575 - 1590
  • [7] Programmed Cell Death Ligand 1 (PD-L1) and Major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in Triple-Negative Breast Cancer
    Kaewkedsri, Ponkrit
    Intarawichian, Piyapharom
    Jessadapattarakul, Sirawich
    Kunprom, Waritta
    Koonmee, Supinda
    Thanee, Malinee
    Somintara, Ongart
    Wongbuddha, Anongporn
    Chadbunchachai, Payia
    Nawapun, Supajit
    Aphivatanasiri, Chaiwat
    BREAST CANCER-TARGETS AND THERAPY, 2025, 17 : 123 - 143
  • [8] Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    Bomze, David
    Azoulay, Daniel
    Meirson, Tomer
    JAMA ONCOLOGY, 2020, 6 (07) : 1114 - 1115
  • [9] Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
    Fang, Xiao-Na
    Fu, Li-Wu
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (02) : 141 - 151
  • [10] Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma
    Villasboas, Jose Caetano
    Ansell, Stephen
    CANCER JOURNAL, 2016, 22 (01): : 17 - 22